WHAT IS CLAIMED IS:

1. A nucleic acid agent that down-regulates activity or expression of human Chaserr for use in treating a disease or medical condition associated with Chromodomain Helicase DNA Binding Protein 2 (CHD2) haploinsufficiency in a subject in need thereof, wherein the nucleic acid agent is directed at the last exon of human Chaserr.

2. A nucleic acid agent that activity or expression of human Chaserr, wherein the nucleic acid agent comprises a nucleic acid sequence that hybridizes at the last exon of human Chaserr.

3. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-2, wherein said human Chaserr comprises an alternatively spliced variant selected from the group consisting of SEQ ID NO: 11 (NR_037600), SEQ ID NO: 12 (NR_037601), and SEQ ID NO: 13 (NR_037602).

4. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-3, wherein said nucleic acid agent comprises a sequence that is complementary to SEQ ID NO: 2 (AUGG).

5. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-3, wherein said nucleic acid agent comprises a sequence that is complementary to AAGAUG (SEQ ID NO: 5) or AAAUGGA (SEQ ID NO: 6).

6. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-5, wherein said nucleic acid agent inhibits binding of DHX36 to Chaserr.

7. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-5, wherein said nucleic acid agent inhibits binding of CHD2 to Chaserr.

8. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-6, wherein said nucleic acid agent is an antisense oligonucleotide and optionally comprises one

or more nucleotides having a 2' to 4' bridge, and/or one or more nucleotides having a 2'-O modification.

9. The nucleic acid agent for, or nucleic acid agent use of claim 6, wherein said antisense oligonucleotide is as set forth in SEQ ID NO: 92-99.

10. The nucleic acid agent for use, or nucleic acid agent of claim 7, wherein said antisense oligonucleotide is as set forth in SEQ ID NO: 128, 131, 132, 133, 140, 141, 142 or 143.

11 The nucleic acid agent for use, or nucleic acid agent of any one of claims 8, and 9, wherein said antisense oligonucleotide comprises at least 2 antisense oligonucleotides.

12. The nucleic acid agent for use, or nucleic acid agent of claim 11, wherein said at least 2 antisense oligonucleotides comprise ASO40 of SEQ ID NO: 140 or 128 and ASO41 of SEQ ID NO: 144 or 134.

13. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-7, wherein said nucleic acid agent is an RNA silencing agent or a genome editing agent.

14. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-13, wherein said nucleic acid agent is active in an inducible manner or in a tissue or cell-specific manner.

15. The nucleic acid agent for use, or nucleic acid agent of any one of claims 1-14, wherein said disease or medical condition associated with Chromodomain Helicase DNA Binding Protein 2 (CHD2) haploinsufficiency is selected from the group consisting of intellectual disability, autism, epilepsy and Lennox–Gastaut syndrome (LGS).